UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis

Clinical infectious diseases, 2007-10, Vol.45 (8), p.1001-1007

2007

Volltextzugriff (PDF)

Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous Meningitis

Clinical infectious diseases, 2009-10, Vol.49 (7), p.1080-1082

2009

Volltextzugriff (PDF)

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

The European respiratory journal, 2011-10, Vol.38 (4), p.888-894

2011

Volltextzugriff (PDF)

Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected Patients

Clinical pharmacology and therapeutics, 2008-07, Vol.84 (1), p.75-82

2008

Volltextzugriff (PDF)

Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients

Antimicrobial agents and chemotherapy, 2015-06, Vol.59 (6), p.3233-3239

2015

Volltextzugriff (PDF)

Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique

European journal of clinical pharmacology, 2015-07, Vol.71 (7), p.811-816

2015

Volltextzugriff (PDF)

Community vs. facility-based directly observed treatment for tuberculosis in Tanzania's Kilimanjaro Region

The international journal of tuberculosis and lung disease, 2009-12, Vol.13 (12), p.1524

2009

Volltextzugriff (PDF)

Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin

International journal of antimicrobial agents, 2014-09, Vol.44 (3), p.229-234

2014

Volltextzugriff (PDF)

Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment

International journal of antimicrobial agents, 2019-09, Vol.54 (3), p.371-374

2019

Volltextzugriff (PDF)

Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes

Clinical infectious diseases, 2006-10, Vol.43 (7), p.848-854

2006

Volltextzugriff (PDF)

Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections

International journal of antimicrobial agents, 2013-09, Vol.42 (3), p.256-261

2013

Volltextzugriff (PDF)

High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets

AIDS (London), 2008-05, Vol.22 (8), p.931-935

2008

Volltextzugriff (PDF)

A STEP-WISE APPROACH TO FIND A VALID AND FEASIBLE METHOD TO DETECT NON-ADHERENCE TO TUBERCULOSIS DRUGS

Southeast Asian journal of tropical medicine and public health, 2008-11, Vol.39 (6), p.1083-1087

2008

Volltextzugriff (PDF)

Pharmacokinetics, food intake requirements and tolerability of once‐daily combinations of nelfinavir and low‐dose ritonavir in healthy volunteers

British journal of clinical pharmacology, 2003-02, Vol.55 (2), p.115-125

2003

Volltextzugriff (PDF)

Acute intoxication patients presenting to an emergency department in the Netherlands: admit or not? Prospective testing of two algorithms

Emergency medicine journal : EMJ, 2012-06, Vol.29 (6), p.467-472

2012

Volltextzugriff (PDF)

Effect of mild diarrhea on tacrolimus exposure

Transplantation, 2012-10, Vol.94 (7), p.763-767

2012

Volltextzugriff (PDF)

Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania

Journal of antimicrobial chemotherapy, 2011-08, Vol.66 (8), p.1810-1814

2011

Volltextzugriff (PDF)

Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers

Clinical pharmacology and therapeutics, 2005-12, Vol.78 (6), p.664-674

2005

Volltextzugriff (PDF)

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations

Therapeutic drug monitoring, 2003-02, Vol.25 (1), p.73-80

2003

Volltextzugriff (PDF)

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy Volunteers

Clinical pharmacology and therapeutics, 2002-01, Vol.71 (1), p.57-67

2002

Volltextzugriff (PDF)

Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir

Antiviral therapy, 2003-08, Vol.8 (4), p.309-314

2003

Volltextzugriff (PDF)

Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis Patients

Antimicrobial Agents and Chemotherapy, 2007-07, Vol.51 (7), p.2546-2551

2007

Volltextzugriff (PDF)

Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure

Clinical pharmacokinetics, 2016-06, Vol.55 (6), p.723-733

2016

Volltextzugriff (PDF)

Plasma Drug Activity Assay for Treatment Optimization in Tuberculosis Patients

Antimicrobial Agents and Chemotherapy, 2011-12, Vol.55 (12), p.5819-5825

2011

Volltextzugriff (PDF)

Delayed trough level measurement with the use of prolonged‐release tacrolimus

Transplant international, 2015-03, Vol.28 (3), p.314-318

2015

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

Humans
(27)
Adult
(26)
Life Sciences & Biomedicine
(25)
Male
(25)
Science & Technology
(25)
Female
(22)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Infectious Diseases
(16)
Pharmacology. Drug Treatments
(16)
Pharmacology & Pharmacy
(15)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(13)
Microbiology
(11)
Adolescent
(10)
Bacterial Diseases
(10)
Human Bacterial Diseases
(10)
Tuberculosis And Atypical Mycobacterial Infections
(10)
Aged
(9)
Pharmacokinetics
(8)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis

Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous Meningitis

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected Patients

Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients

Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique

Community vs. facility-based directly observed treatment for tuberculosis in Tanzania's Kilimanjaro Region

Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin

Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment

Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes

Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections

High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets

A STEP-WISE APPROACH TO FIND A VALID AND FEASIBLE METHOD TO DETECT NON-ADHERENCE TO TUBERCULOSIS DRUGS

Pharmacokinetics, food intake requirements and tolerability of once‐daily combinations of nelfinavir and low‐dose ritonavir in healthy volunteers

Acute intoxication patients presenting to an emergency department in the Netherlands: admit or not? Prospective testing of two algorithms

Effect of mild diarrhea on tacrolimus exposure

Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania

Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy Volunteers

Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir

Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis Patients

Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure

Plasma Drug Activity Assay for Treatment Optimization in Tuberculosis Patients

Delayed trough level measurement with the use of prolonged‐release tacrolimus

Aktive Filter

Suchergebnisse filtern